MAP2K1 and colorectal carcinoma: The Cancer Genome Atlas (TCGA) has reported MAP2K1 mutations in a high percentage (2.4%; 13/549) of CRC cases (40, 42, 43), while other studies have shown incidence varying from 1% to 2% (20–22).